Cocrystal pharma completes ind-enabling studies with cc-42344 for the treatment of seasonal and pandemic influenza a, plans to initiate a phase 1 trial in the third quarter

Bothell, wash., june 23, 2021 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis c viruses and noroviruses, announces the completion of ind-enabling studies with its potent, broad-spectrum pb2 inhibitor cc-42344 for the treatment of seasonal and pandemic influenza a and plans to initiate phase 1 clinical development of cc-42344 in the third quarter of 2021.
COCP Ratings Summary
COCP Quant Ranking